EU approves GSK's once-weekly diabetes drug

(Reuters) - GlaxoSmithKline Plc said on Wednesday that it had received European marketing approval for its once-weekly diabetes drug albiglutide, which it is marketing as Eperzan. The drug received a positive recommendation from the European Medicines Agency (EMA) in January. GSK said it expects to launch albiglutide in several countries in Europe in the third to fourth quarter this year. Albiglutide is currently under review by the US Food and Drug Administration (FDA), which is expected to give its opinion on the drug by April 15.



via Health News Headlines - Yahoo News http://ift.tt/1o0W1Si